Market Overview

UPDATE: Brinson Patrick Initiates Coverage on MannKind Corporation with Market Outperform Rating, $6 PT

Related MNKD
MannKind Disappoints Again With Afrezza Sales
MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
Pharmacyte Biotech is Redefining the Term "Diabetes Treatment" (PMCB, NVO, MNKD) (Small Cap Network)

In a report published Monday, Brinson Patrick initiated coverage on MannKind Corporation (NASDAQ: MNKD) with a Market Outperform rating and $6.00 price target.

Brinson Patrick noted, “MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares.”

MannKind Corporation closed on Friday at $2.13.

Latest Ratings for MNKD

Mar 2015Goldman SachsDowngradesNeutralSell
Oct 2014Goldman SachsInitiates Coverage onNeutral
Aug 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Brinson PatrickAnalyst Color Initiation Analyst Ratings


Related Articles (MNKD)

Around the Web, We're Loving...